Loading...
Market
Story
Eli Lilly's Mounjaro Approved for Hong Kong Launch by Year-End 2024, Stock at $LLY
Oct 28, 2024, 01:08 AM
Eli Lilly & Co. has received approval to launch its weight-loss drug, Mounjaro, in Hong Kong, with sales expected to begin by the end of 2024. This development marks a significant milestone as it positions Mounjaro to be the first weight-loss drug of its kind available in the China region. The approval comes amid ongoing discussions regarding the broader implications of drug shortages and FDA oversight, as highlighted by recent reports. Eli Lilly's stock, trading under the ticker $LLY, is closely monitored as the company expands its market presence.
View original story
Similar markets
Novo Nordisk • 34%
Eli Lilly • 33%
Other • 33%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Mounjaro > 50% • 25%
Mounjaro 30-50% • 25%
Mounjaro 10-30% • 25%
Mounjaro < 10% • 25%
Zepbound • 25%
Wegovy • 25%
Saxenda • 25%
Other • 25%
MariTide leads market share • 25%
Eli Lilly leads market share • 25%
Novo Nordisk leads market share • 25%
Market share is evenly distributed • 25%
Roche's CT-996 has the largest market share • 25%
Novo Nordisk has the largest market share • 25%
Eli Lilly has the largest market share • 25%
Other companies have the largest market share • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Above 50% • 25%
30%-50% • 25%
10%-30% • 25%
Below 10% • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%